Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

Clin Pharmacol Ther. 2017 Mar;101(3):341-358. doi: 10.1002/cpt.602.


Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into routine care remains limited. Opportunely, several implementation studies and programs have been initiated over recent years. This article presents an overview of these studies and identifies current research gaps. Importantly, one such gap is the undetermined collective clinical utility of implementing a panel of PGx-markers into routine care, because the evidence base is currently limited to specific, individual drug-gene pairs. The Ubiquitous Pharmacogenomics (U-PGx) Consortium, which has been funded by the European Commission's Horizon-2020 program, aims to address this unmet need. In a prospective, block-randomized, controlled clinical study (PREemptive Pharmacogenomic testing for prevention of Adverse drug REactions [PREPARE]), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which guidelines are available, will be implemented across healthcare institutions in seven European countries. The impact on patient outcomes and cost-effectiveness will be investigated. The program is unique in its multicenter, multigene, multidrug, multi-ethnic, and multihealthcare system approach.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Cost-Benefit Analysis
  • Electronic Health Records / organization & administration
  • Europe
  • Genotype
  • Humans
  • Pharmacogenomic Testing / economics
  • Pharmacogenomic Testing / methods*
  • Pharmacogenomic Testing / statistics & numerical data*
  • Pharmacogenomic Testing / trends
  • Practice Guidelines as Topic
  • Precision Medicine / methods
  • Prospective Studies
  • Research Design*
  • Treatment Outcome


  • Biomarkers